LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/Amedica Launches New Fusion Devices
Spine

Amedica Launches New Fusion Devices

October 9, 2012 2 min read Premium comments

Advertisement

Amedica Launches New Fusion Devices
Interbody Fusion Device (IFD) Courtesy of Amedica Corporation
Secondary

Amedica Corporation, a spinal and reconstructive implant manufacturer, has received 510(k) clearance from the FDA to market the firm’s second generation family of cervical and lumbar interbody fusion devices (IBF). An interbody fusion device is prosthesis to restore and maintain disc space height following a spinal decompression while fusion occurs. Spinal fusions are performed to eliminate the pain caused by abnormal motion of the vertebrae as a result of diseased discs, slippage of the vertebrae, or other degenerative spinal conditions. The goal is to immobilize the faulty vertebrae themselves. Amedica launched its first generation of implants four years ago and inserted about 8, 500 devices.

Eric Olson, president and CEO of Amedica, told OTW that “the second generation is a complete redesign of our entire family of interbody devices. From cervical to lumbar there are new angles, new footprints, new design features for enhanced fixation—primarily the insertion method for these interbody devices. For the first time that I am aware of in industry, our manufacturing plant has been able to thread ceramic (silicon nitride) material. It allows us to put all of our interbody devices on a threaded inserter so surgeons can have more precise placement of the device and also easier extraction of the device if that were ever necessary.”

The FDA ruling also includes clearance for marketing an extreme lateral device (LLIF) which, according to Olsen, allows the firm to enter a $147 million market. Olsen suggests that minimally invasive LLIF procedures may offer improved patient outcomes by allowing reduced operative time, post-operative pain and hospital stays, as well as a rapid return to normal activity.

Among the challenges in performing an LLIF procedure is the proximity to nerves during implantation which requires the use of neuromonitoring to ensure precise, safe placement of the implant. Silicon nitride, Olsen says, is semi-radiolucent which enables an exact view of the implant for precise intraoperative positioning, thereby alleviating this challenge. Amedica officials also claim that silicon nitride provides superior osteointegration and anti-infective characteristics than do products made from poly-ether-ether-ketone (PEEK) or titanium (T).

Amedica Corporation is a privately held, private equity-backed company founded in 1996 and located in Salt Lake City, Utah. The company is ISO 13485 certified, its spine products are FDA cleared, CE marked, and sold in ten countries.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy